Hikma Pharmaceuticals Plc Further re Colchicine Litigation (7584Y)
May 19 2016 - 7:15AM
UK Regulatory
TIDMHIK
RNS Number : 7584Y
Hikma Pharmaceuticals Plc
19 May 2016
Hikma wins Mitigare / Colchicine patent infringement case
London, 19 May 2016 - Hikma Pharmaceuticals PLC (Hikma) (LSE:
HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), (rated Ba1 Moody's / BB+
S&P, both stable), the fast growing multinational
pharmaceutical group, today announces that the United States
District Court for the District of Delaware has ruled in favour of
Hikma and its wholly-owned subsidiary in the United States,
West-Ward Pharmaceutical Corp., by granting their motion to dismiss
claims made by Takeda Pharmaceuticals USA, Inc. for alleged
infringement of patents covering methods of use of Takeda's
colchicine product, Colcrys(R).
Since January 2015, Hikma has been marketing its own colchicine
product under the brand name Mitigare(TM), as well as selling an
authorised generic, increasing patient access to this important
product in the United States.
Said Darwazah, Chairman and CEO of Hikma, said:
"I am very pleased with the ruling of the Delaware Court. This
is a successful outcome and demonstrates our commitment to bringing
more differentiated products to the US market."
-- ENDS --
Enquiries
Hikma Pharmaceuticals PLC
Susan Ringdal, VP Corporate Strategy and Investor Relations +44
(0)20 7399 2760/ +44 7776 477050
Zeena Murad, Investor Relations Manager +44 (0) 20 7399 2768/
+44 7771 665277
FTI Consulting
Ben Atwell/ Matthew Cole / Julia Phillips +44 (0)20 3727
1000
About Hikma
Hikma Pharmaceuticals PLC is a fast growing multinational group
focused on developing, manufacturing and marketing a broad range of
both branded and non-branded generic and in-licensed products.
Hikma operates through three businesses: "Injectables", "Branded"
and "Generics", based principally in the United States, the Middle
East and North Africa (MENA) and Europe. In 2015, Hikma achieved
revenues of $1,440 million and profit attributable to shareholders
of $252 million.
This information is provided by RNS
The company news service from the London Stock Exchange
END
FURAKCDDDBKDQPD
(END) Dow Jones Newswires
May 19, 2016 07:15 ET (11:15 GMT)
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024